Some success shown in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2 by preliminary findings from the first trial of a new drug for patients with mesothelioma. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
Mesothelioma, which is usually caused by exposure to asbestos, has few treatment options and patients usually die within 9-17 months of diagnosis....
Some success shown in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2 by preliminary findings from the first trial of a new drug for patients with mesothelioma. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
Mesothelioma, which is usually caused by exposure to asbestos, has few treatment options and patients usually die within 9-17 months of diagnosis....